Drug
Paclitaxel （neoadjuvant）
Paclitaxel （neoadjuvant） is a pharmaceutical drug with 3 clinical trials. Currently 2 active trials ongoing.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
2(67%)
Phase Distribution
No phase data available
Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
3
all time
Status Distribution
Active(2)
Other(1)
Detailed Status
Recruiting2
unknown1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
2
Success Rate
N/A
Trials by Status
unknown133%
recruiting267%
Recent Activity
2 active trials
Showing 3 of 3
recruiting
Effects of Neoadjuvant Therapy With Carboplatin, Paclitaxel Combined With Anti-PD-1 Drugs on Cognitive Function in Patients With Resectable Head and Neck Squamous Cell Carcinoma
NCT06576180
recruiting
Effects of Neoadjuvant Therapy With Carboplatin, Paclitaxel Combined With Anti-PD-1 Drugs on Pain, Anxiety and Depression in Patients With Resectable Head and Neck Squamous Cell Carcinoma
NCT06575322
unknown
Early On-treatment Transcriptional Profiling as Predictor of Response in Early-stage HER2-positive Breast Cancer
NCT05912062
Clinical Trials (3)
Showing 3 of 3 trials
NCT06576180
Effects of Neoadjuvant Therapy With Carboplatin, Paclitaxel Combined With Anti-PD-1 Drugs on Cognitive Function in Patients With Resectable Head and Neck Squamous Cell Carcinoma
NCT06575322
Effects of Neoadjuvant Therapy With Carboplatin, Paclitaxel Combined With Anti-PD-1 Drugs on Pain, Anxiety and Depression in Patients With Resectable Head and Neck Squamous Cell Carcinoma
NCT05912062
Early On-treatment Transcriptional Profiling as Predictor of Response in Early-stage HER2-positive Breast Cancer
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3